Losartan is a prescription treatment primarily used to help manage specific conditions related to the heart and circulatory system. The medication is officially indicated for the management of high blood pressure (hypertension), for controlling factors associated with stroke risk in patients who have hypertension along with an enlarged heart (left ventricular hypertrophy), and for managing diabetic kidney disease (nephropathy) in individuals with type 2 diabetes and a history of high blood pressure.

The therapeutic goal for the patient is assistance in maintaining lower, controlled blood pressure levels. This management is an important step in a long-term care plan for cardiovascular health. Clinical data indicates that:

“…lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.”

---

Quick Fact: Relief for Elevated Blood Pressure

Losartan eligibility is strictly defined by regulatory authorities based on age, physiological status, and specific comorbidities.

Populations for whom use is Contraindicated

• Pregnancy: Use is contraindicated during the second and third trimesters. Treatment must be discontinued as soon as pregnancy is detected.
• Hypersensitivity: Patients with a known allergy to losartan or any component of the formulation.
• Concomitant Therapy: Patients with Diabetes Mellitus who are receiving Aliskiren.
• Severe Hepatic Impairment: Contraindicated (per European labeling). The drug has not been investigated in this patient population.

Age-Related Eligibility Rules

• Pediatric Use: Permitted for hypertension treatment only in children aged 6 to 18 years.
• Not Recommended: Use is not recommended in children younger than 6 years or in pediatric patients with a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73 m^2 (due to insufficient data).

Eligibility-Related Restrictions

• Hepatic Impairment (Mild-to-Moderate): Use requires a lower initial dose.
• Volume Depletion: Patients who are volume-depleted (e.g., on high-dose diuretics) require a lower initial dose.
• Lactation: Use is not recommended.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Losartan primarily through absolute contraindications tied to reproductive status and drug-drug interactions in specific comorbid conditions. Eligibility is further constrained by age, excluding children under six, and by restrictions based on organ function, which mandate special consideration in these patient groups.

Interactions with other medicines and products

The official interaction profile for Losartan is defined by its metabolic clearance and its influence on electrolyte balance, as documented in regulatory information.

---

Contraindicated and High-Risk Combinations

Formal contraindications exist for co-administration with Aliskiren in patients diagnosed with diabetes mellitus or moderate-to-severe renal impairment. Co-administration with Sparsentan is also formally prohibited due to documented pharmacodynamic reinforcement.

Substances such as potassium-sparing diuretics (e.g., Spironolactone) and potassium supplements pose an additive risk of hyperkalemia (high serum potassium levels). This electrolyte-related pharmacodynamic interaction requires restriction of their co-administration.

---

Pharmacokinetic and Exposure Modification

Co-administration with inhibitors or inducers of CYP2C9 and CYP3A4 enzymes alters the drug's systemic exposure. For instance, Fluconazole is documented to increase parent Losartan exposure while reducing the systemic exposure of its active metabolite. Conversely, inducers like Rifampin decrease the exposure of both compounds.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect and concurrently increase the risk of renal function deterioration. Furthermore, co-administration with Lithium is documented to decrease its renal clearance, increasing the risk of toxicity. Exposure of Losartan is also significantly increased in populations with hepatic impairment due to documented reduced clearance.

Molecular Mechanism and Pathway Modulation

Losartan functions primarily as an Angiotensin II Receptor Blocker (ARB), exerting its effect by acting as an antagonist at the Angiotensin II Type 1 ( AT1) receptor. This receptor is the key signaling target for the hormone Angiotensin II within the vascular smooth muscle, adrenal glands, and kidneys. By blocking the AT1 receptor, Losartan interrupts the final and most powerful efferent step of the Renin-Angiotensin-Aldosterone System (RAAS) hormonal cascade. This action prevents Angiotensin II from initiating G-protein signaling, which normally causes vasoconstriction and stimulates aldosterone release.

Systemic Physiological Consequences

Interruption of this cascade leads to two main physiological changes: relaxation of the arterial smooth muscle tissue, resulting in vasodilation and a reduction in systemic vascular resistance; and decreased Aldosterone secretion, which promotes the renal excretion of sodium and water. These modulations alter systemic hemodynamics by reducing both the pressure and volume load on the circulatory system. Separately, Losartan also acts as an inhibitor of the renal URAT1 transporter, decreasing the reabsorption of uric acid and resulting in its increased clearance into the plasma.

How Losartan is Used

Losartan is administered exclusively via the oral route, primarily as film-coated tablets in strengths of 25 mg, 50 mg, and 100 mg. The medication is used as a once-daily therapy for all approved indications, maintaining consistent blood levels over a 24-hour period. For consistent administration, the dose is generally taken around the same time each day and may be taken irrespective of meals.

Treatment follows a specific titration protocol. The standard adult starting dose is 50 mg once daily for hypertension, diabetic nephropathy, and stroke risk reduction. However, a lower initial dose of 25 mg once daily is specified for patients with intravascular volume depletion or mild-to-moderate hepatic impairment. The dosage may subsequently be increased to the maximum recommended daily dose of 100 mg once daily, based on procedural response. The full blood pressure-lowering effect may require three to six weeks of continuous therapy to achieve.

For pediatric patients (aged 6 to 16 years), the initial dose is weight-based at 0.7 mg/kg once daily, with the ability to adjust up to a maximum of 100 mg per day. A prepared oral suspension, which requires refrigeration, is available for children unable to swallow tablets. Losartan is generally used as part of a long-term management protocol.

Recent Clinical Evidence: Losartan

Clinical research and large-scale trials have investigated losartan's use across its primary indications and explored its potential for broader therapeutic applications.

Core Therapeutic Areas

The primary focus of clinical evidence remains in cardiovascular and renal health, where losartan is used to address the effects of Angiotensin II.

• Hypertension and Cardiac Events: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study found that a losartan-based regimen was associated with a greater reduction in the composite endpoint of cardiovascular death, myocardial infarction, and stroke compared to an atenolol-based regimen, with most of the benefit driven by a reduction in stroke risk in patients with hypertension and left ventricular hypertrophy. Both treatment groups achieved similar blood pressure reductions.
• Diabetic Nephropathy: Studies conducted in patients with Type 2 diabetes and hypertension have investigated losartan's effects on kidney function. Evidence indicates its use in this population is associated with a lower rate of decline in kidney function and reduction in proteinuria (protein in the urine).

Emerging Research Areas

Recent investigations have explored the drug's role in conditions beyond its primary indications, based on its interaction with the renin-angiotensin system:

• Alzheimer's Disease: The RADAR trial was a double-blind, randomized, placebo-controlled Phase 2 trial that investigated losartan's potential to reduce the rate of brain volume loss in individuals with mild-to-moderate Alzheimer's disease. The trial suggested that treatment over 12 months, while generally accepted by patients, did not significantly affect the primary outcome of reducing brain atrophy compared to placebo.
• Other Exploratory Studies: Ongoing research in various models has sought to understand the drug's influence on connective tissue disorders and neurological conditions, though definitive clinical evidence in these areas is still limited or inconclusive.

Common questions about Лозартан (FAQ)

Q: Can I continue taking Losartan if my blood pressure has already become normal?

Losartan is typically intended for long-term use as a management protocol, rather than a temporary cure. Official patient information emphasizes the importance of continuing the medication regularly as prescribed to maintain consistent blood pressure control. Sudden discontinuation is generally discouraged due to the risk of blood pressure rebound.

Q: Does Losartan cause a cough, like some other blood pressure medicines?

Studies included in regulatory information have investigated the occurrence of cough with Losartan, particularly compared to older blood pressure medications (ACE inhibitors). Official drug information indicates that because Losartan acts via a different mechanism, it was explored for use in patients who experienced cough with previous treatments.

Q: If I miss a dose of Losartan, what should I do?

Official patient instructions describe the proper procedure for missed doses. Regulatory guidance suggests taking the dose if it is remembered. However, if the time is close to the next scheduled dose, the missed dose should be skipped, and the patient should resume the regular schedule. Taking a double dose is not advised.

Q: Does Losartan affect the ability to drive or operate machinery?

Regulatory labeling notes that Losartan may cause side effects such as dizziness or drowsiness (fatigue is a common side effect). Because of these potential effects, it is generally recommended that individuals ascertain how they personally react to the medicine before engaging in activities that require full alertness, such as driving or operating heavy machinery.

Q: Can Losartan affect blood sugar levels in people with diabetes?

Losartan is approved for use in patients with type 2 diabetes for the treatment of diabetic kidney disease (nephropathy). Due to its use in this population, official regulatory warnings indicate that monitoring is necessary to check certain metabolic parameters, including those related to diabetes management.

Q: Is it acceptable to consume alcohol while taking Losartan?

Official patient information states that consuming alcohol may contribute to the blood pressure-lowering effect of Losartan. This additive effect may increase the likelihood of experiencing symptoms such as dizziness or feeling faint.

Q: Why is Losartan sometimes prescribed in combination with another medicine, such as a diuretic?

Losartan is available as a combination product with a diuretic, such as hydrochlorothiazide. This combination is typically specified in regulatory indications for patients who may benefit from the additional blood pressure control provided by two different medications.

Q: Are there any known long-term risks associated with taking Losartan for many years?

Losartan is a treatment intended for the long-term management of chronic conditions. Official labeling includes all known risks and side effects that have been assessed based on continuous use data collected over time in clinical studies and post-marketing surveillance.

Q: Is it true that Losartan may be less effective for some ethnic groups?

Studies included in regulatory labeling have examined the drug's effectiveness across various groups. Clinical evidence from the LIFE study specifically observed that the documented benefit related to stroke reduction may not be fully applicable to Black patients with hypertension and left ventricular hypertrophy.

Q: What happens if I suddenly stop taking Losartan?

Regulatory patient counseling information describes the risk of abruptly discontinuing Losartan. Suddenly stopping the medication has been shown to potentially cause blood pressure to increase rapidly, which carries an underlying risk for serious cardiovascular events like a heart attack or stroke.

Q: Why might doctors prescribe Losartan if a patient had side effects with another drug from the ACE inhibitor class?

Losartan belongs to the ARB class, which works via a mechanism different from ACE inhibitors. This difference in action has led to Losartan being studied for its potential use in patients who experienced certain adverse reactions, such as persistent cough, with an ACE inhibitor.

Q: Is Losartan a controlled substance or a substance that causes addiction?

Losartan is a prescription medication used for managing chronic conditions. According to the regulatory classification framework, Losartan is not designated as a controlled or scheduled substance.

Q: How often is it necessary to measure blood pressure when taking Losartan?

Official patient information emphasizes that regular monitoring is necessary during Losartan treatment. This generally includes monitoring blood pressure itself, as well as kidney function, to help ensure the medication is administered effectively and safely.

Q: Can Losartan cause temporary vision changes?

While adverse effects on vision are rare, official warnings note that the combination product of Losartan and a diuretic carries a cautionary statement regarding serious eye conditions, including acute myopia and secondary angle-closure glaucoma.

Storage and Disposal Conditions for Losartan Potassium

Losartan potassium tablets must be stored at Controlled Room Temperature, specifically 25 C (77 F), with permissible temperature excursions ranging from 15 C to 30 C (59 F to 86 F). The product must be protected from light and kept away from excessive moisture.

Storage Component	Regulatory Requirement
Temperature	Controlled Room Temperature (15 C to 30 C)
Container	Keep in original container and tightly closed
Safety	Keep out of the sight and reach of children

For stability, the medication must remain in its tightly closed container to maintain integrity until the expiration date. Disposal of unused or expired Losartan should utilize a drug take-back program or official collection point. If a take-back option is not available, the medication can be discarded in household trash by following specific regulatory steps; Losartan is not on the list of medicines recommended for immediate flushing.